Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, David; Humblet, Yves; Siena, Salvatore; Khayat, David; Bleiberg, Harry; Santoro, Armando; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, Chris; Chau, Ian; Van Cutsem, Eric

doi:10.1056/nejmoa033025

Public

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Published in New England Journal of Medicine • Jul 21, 2004

Authors:

David Cunningham

Yves Humblet

Salvatore Siena

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in combinat...

Subject

Cetuximab

Irinotecan

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!